Revvity Receivables 2010-2025 | RVTY

Revvity receivables for the quarter ending March 31, 2025 were $0.617B, a 4.83% increase year-over-year.

  • Revvity receivables for 2024 were $0.632B, a 0.06% decline from 2023.
  • Revvity receivables for 2023 were $0.633B, a 3.27% increase from 2022.
  • Revvity receivables for 2022 were $0.613B, a 13.44% decline from 2021.

Revvity Receivables 2010-2025 | RVTY

  • Revvity receivables for 2024 were $0.632B, a 0.06% decline from 2023.
  • Revvity receivables for 2023 were $0.633B, a 3.27% increase from 2022.
  • Revvity receivables for 2022 were $0.613B, a 13.44% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$141.5B
CVS Health (CVS)$81.4B
Elevance Health (ELV)$76.8B
Cencora (COR)$57.6B
DiDi Global (DIDIY)$25.2B
Natera (NTRA)$21.6B
Labcorp Holdings (LH)$20.9B
BioMerieux (BMXMF)$16.9B
EUROFINS SCIENT (ERFSF)$13.3B
CochLear (CHEOY)$13B
Solventum (SOLV)$12.8B
ICON (ICLR)$12.1B
Viatris (VTRS)$10.7B
Medpace Holdings (MEDP)$9.2B
Avantor (AVTR)$9B
Sonic Healthcare (SKHHY)$8.8B
HealthEquity (HQY)$8.4B
Charles River Laboratories (CRL)$7.8B
Caris Life Sciences,�Inc (CAI)$7.1B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.8B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.3B
Surgery Partners (SGRY)$2.9B
Alignment Healthcare (ALHC)$2.7B
Concentras Parent (CON)$2.6B
Organon (OGN)$2.6B
GeneDx Holdings (WGS)$2.4B
Ardent Health (ARDT)$2.1B
Progyny (PGNY)$2B